Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyoscine for clozapine-induced sialorrhea in schizophrenia
IRCT20191218045795N3Phase 3Completed
- Sponsor
- Kurdistan University of Medical Sciences
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of hyoscine butylbromide in hypersalivation (2 arms), sponsored by Kurdistan University of Medical Sciences. Primary endpoints: Measure of sialorrhea by DRS Scale and Mini Mental State Scale. Started Sep 2019; status: completed.
02
Drugs
hyoscine butylbromide
03
Conditions
hypersalivation
Beyond the preview
Go deeper on IRCT20191218045795N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191218045795N3.